Erasca (ERAS) EBT (2020 - 2026)
Erasca's (ERAS) quarterly EBT came in at -$860.7 million in Q1 2026, down 2218.06% YoY from $40.6 million in Q1 2025, and down 2423.74% on a QoQ basis from -$34.1 million in Q4 2025.
Erasca (ERAS) EBT (2020 - 2026) Analysis & Trends
Erasca (ERAS) has 7 years of EBT data on file, last reported at -$860.7 million in Q1 2026.
- Quarterly EBT fell 2218.06% year-over-year to -$860.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.0 billion (down 267.67% YoY) and the FY2025 annual result came in at -$383.1 million, down 98.94% from the prior year.
- EBT retreated to -$860.7 million in Q1 2026, from -$34.1 million in the prior quarter.
- In the past five years, EBT ranged from a high of -$29.4 million in Q4 2023 to a low of -$860.7 million in Q1 2026.
- A 5-year average of -$118.3 million and a median of -$55.7 million in 2025 frame the typical range for EBT.
- Annual changes were most pronounced in 2023 — EBT surged 78.8% — and 2026, when it slumped 2218.06%.
- Tracing ERAS's EBT over 5 years: stood at -$138.7 million in 2022, then surged by 78.8% to -$29.4 million in 2023, then dropped by 27.25% to -$37.4 million in 2024, then advanced by 8.84% to -$34.1 million in 2025, then tumbled by 2423.74% to -$860.7 million in 2026.
- The last three EBT figures came in at -$860.7 million (Q1 2026), -$34.1 million (Q4 2025), and -$51.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 541.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 312.46 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2,828.29 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 177.81 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -11.37 Mn |
| 10 | Erasca | 6.43 Bn | 6.16 Bn | - | -856.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -856.21 Mn |
| Mar 31, 2026 | -860.70 Mn |
| Dec 31, 2025 | -34.10 Mn |
| Sep 30, 2025 | -51.08 Mn |
| Jun 30, 2025 | -55.74 Mn |
| Mar 31, 2025 | -37.13 Mn |
| Dec 31, 2024 | -37.41 Mn |
| Sep 30, 2024 | -53.90 Mn |
| Jun 30, 2024 | -143.98 Mn |
| Mar 31, 2024 | -46.38 Mn |
| Dec 31, 2023 | -29.40 Mn |
| Sep 30, 2023 | -60.57 Mn |
| Jun 30, 2023 | -120.78 Mn |
| Mar 31, 2023 | -45.78 Mn |
| Dec 31, 2022 | -138.69 Mn |
| Sep 30, 2022 | -124.98 Mn |
| Jun 30, 2022 | -66.60 Mn |
| Mar 31, 2022 | -103.70 Mn |
| Dec 31, 2021 | -31.96 Mn |
| Sep 30, 2021 | -288.26 Mn |